X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3920) 3920
Newspaper Article (17) 17
Magazine Article (11) 11
Book Chapter (9) 9
Book Review (5) 5
Newsletter (4) 4
Book / eBook (1) 1
Dissertation (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3351) 3351
female (2187) 2187
male (1587) 1587
osteoporosis (1508) 1508
fractures (1315) 1315
aged (1301) 1301
middle aged (1283) 1283
risk factors (1037) 1037
osteoporosis - chemically induced (1011) 1011
bone density - drug effects (815) 815
adult (697) 697
endocrinology & metabolism (687) 687
risk (614) 614
orthopedics (604) 604
fractures, bone - chemically induced (602) 602
animals (567) 567
bone-mineral density (563) 563
aged, 80 and over (562) 562
bone density conservation agents - adverse effects (553) 553
osteoporosis - drug therapy (541) 541
glucocorticoids - adverse effects (531) 531
postmenopausal women (531) 531
bone density (489) 489
fracture (488) 488
bone density conservation agents - therapeutic use (485) 485
diphosphonates - adverse effects (476) 476
women (465) 465
rheumatology (445) 445
medicine & public health (432) 432
bones (423) 423
medicine, general & internal (411) 411
diphosphonates - therapeutic use (403) 403
therapy (366) 366
bisphosphonates (356) 356
research (352) 352
alendronate (350) 350
prevention (332) 332
mineral density (327) 327
fractures, bone - prevention & control (326) 326
osteoporosis - prevention & control (326) 326
bone (323) 323
treatment outcome (323) 323
care and treatment (322) 322
drug therapy (320) 320
density (317) 317
health aspects (317) 317
time factors (312) 312
bone mineral density (294) 294
hip fracture (289) 289
abridged index medicus (282) 282
endocrinology (278) 278
fractures, bone - etiology (278) 278
radiography (277) 277
retrospective studies (274) 274
femoral fractures - chemically induced (273) 273
corticosteroids (272) 272
complications and side effects (261) 261
analysis (256) 256
risk assessment (254) 254
fractures, bone - epidemiology (253) 253
osteoporosis - complications (248) 248
adolescent (239) 239
bone density conservation agents - administration & dosage (235) 235
double-blind (235) 235
osteoporosis, postmenopausal - drug therapy (235) 235
zoledronic acid (230) 230
rats (225) 225
surgery (220) 220
pharmacology & pharmacy (217) 217
fracture risk (216) 216
dose-response relationship, drug (213) 213
incidence (205) 205
bone and bones - drug effects (204) 204
absorptiometry, photon (201) 201
diphosphonates - administration & dosage (200) 200
drug administration schedule (197) 197
follow-up studies (190) 190
calcium (187) 187
oncology (183) 183
vertebral fractures (183) 183
glucocorticoids (176) 176
case-control studies (175) 175
hip fractures - chemically induced (172) 172
child (169) 169
cohort studies (168) 168
prospective studies (168) 168
fractures, spontaneous - chemically induced (167) 167
osteoporosis - epidemiology (167) 167
usage (165) 165
vertebral fracture (162) 162
cancer (161) 161
glucocorticoid-induced osteoporosis (161) 161
alendronate - adverse effects (159) 159
men (159) 159
vitamin d (159) 159
osteoporosis - physiopathology (158) 158
bone loss (157) 157
corticosteroid-induced osteoporosis (157) 157
adrenal cortex hormones - adverse effects (156) 156
internal medicine (156) 156
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3692) 3692
German (81) 81
Japanese (75) 75
French (60) 60
Spanish (30) 30
Danish (12) 12
Russian (12) 12
Italian (10) 10
Czech (9) 9
Polish (6) 6
Swedish (6) 6
Portuguese (5) 5
Dutch (4) 4
Hungarian (4) 4
Slovak (2) 2
Arabic (1) 1
Chinese (1) 1
Icelandic (1) 1
Korean (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2011, Volume 103, Issue 17, pp. 1299 - 1309
Journal Article
Endocrinology and Metabolism Clinics of North America, ISSN 0889-8529, 09/2012, Volume 41, Issue 3, pp. 595 - 611
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
Men receiving androgen-deprivation therapy for nonmetastatic prostate cancer are at high risk for bone loss and fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 2018, Volume 141, Issue 1, pp. 110 - 116.e7
Background Significant adverse effects (AEs) have been associated with continuous exposure to oral corticosteroids (OCSs). The potential association with... 
Allergy and Immunology | adverse effects | severe asthma | Oral corticosteroids | burst therapy | UNITED-STATES | EVENTS | ALLERGY | DOSE-RESPONSE RELATIONSHIP | INHALED CORTICOSTEROIDS | COMPLICATIONS | IMMUNOLOGY | Cataract - chemically induced | Humans | Middle Aged | Fractures, Bone - epidemiology | Male | Cataract - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Diabetes Mellitus, Type 2 - epidemiology | Hypertension - chemically induced | Adult | Female | Retrospective Studies | Hypertension - epidemiology | Asthma - epidemiology | Osteoporosis - epidemiology | Obesity - chemically induced | Osteoporosis - chemically induced | Administration, Oral | Asthma - drug therapy | Adrenal Cortex Hormones - adverse effects | Gastrointestinal Hemorrhage - chemically induced | Obesity - epidemiology | Diabetes Mellitus, Type 2 - chemically induced | Fractures, Bone - chemically induced | Adrenal Cortex Hormones - administration & dosage | Cataracts | Corticoids | Glaucoma | Systematic review | Metabolic syndrome | Bleeding | Osteoporosis | Biomedical materials | Immunology | Databases | Biocompatibility | Drug dosages | Chronic illnesses | Hypertension | Corticosteroids | Medicare | Diabetes mellitus | Exposure | Patients | Allergies | Asthma | Studies | Side effects | Fractures | Tuberculosis | Ulcers | Diabetes
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article
Journal of bone and mineral research, ISSN 1523-4681, 2015, Volume 30, Issue 9, pp. 1651 - 1656
ABSTRACT Glucocorticoids, widely used in inflammatory disorders, rapidly increase bone fragility and, therefore, fracture risk... 
REFERENCE POINT INDENTATION | ANABOLICS | BONE MATERIAL STRENGTH | CORTICOSTEROIDS | BIOMECHANICS | ANTIRESORPTIVES | bone material strength | anabolics | biomechanics | corticosteroids | antiresorptives | reference point indentation | MANAGEMENT | STRENGTH | MECHANICAL-PROPERTIES | FRACTURE RISK | IN-VIVO MEASUREMENT | MINERAL DENSITY | REDUCTION | STRUCTURAL BASIS | ENDOCRINOLOGY & METABOLISM | POSTMENOPAUSAL WOMEN | FINITE-ELEMENT-ANALYSIS | Bone and Bones - pathology | Bone Density | Osteoporosis - chemically induced | Calcium - metabolism | Humans | Middle Aged | Stress, Mechanical | Male | Reference Values | Bone Density Conservation Agents - administration & dosage | Absorptiometry, Photon | Denosumab - administration & dosage | Bone and Bones - diagnostic imaging | Risedronate Sodium - administration & dosage | Glucocorticoids - chemistry | Adult | Female | Teriparatide - adverse effects | Aged | Densitometry | Fractures, Bone - prevention & control | Glucocorticoids - adverse effects | Measurement | Osteoporosis | Corticosteroids | Vitamin D | Bone densitometry | Calcifediol | Alfacalcidol | Steroids | Dual energy X-ray absorptiometry | Glucocorticoids | Calcium | Bisphosphonates | Fractures | Parathyroid hormone | Tibia | Risedronic acid | Bones | Bone mineral density | Bone density | Bone (cortical) | Osteoporosi | strength | Ciències de la salut | mechanical-properties | Ossos | postmenopausal women | in-vivo measurement | structural basis | Wounds and injuries | fracture risk | mineral density | Teixit ossi | Ferides i lesions | Bone | Medicina | finite-element-analysis | antiresorptive drugs | cortical bone | Àrees temàtiques de la UPC | Glucocorticoides
Journal Article
Journal Article